ATE412657T1 - Therapeutische quinazolin-derivate - Google Patents
Therapeutische quinazolin-derivateInfo
- Publication number
- ATE412657T1 ATE412657T1 AT03789562T AT03789562T ATE412657T1 AT E412657 T1 ATE412657 T1 AT E412657T1 AT 03789562 T AT03789562 T AT 03789562T AT 03789562 T AT03789562 T AT 03789562T AT E412657 T1 ATE412657 T1 AT E412657T1
- Authority
- AT
- Austria
- Prior art keywords
- quinazoline derivatives
- therapeutic
- therapy
- processes
- formula
- Prior art date
Links
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical class N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
- C07F9/65128—Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02293240 | 2002-12-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE412657T1 true ATE412657T1 (de) | 2008-11-15 |
Family
ID=32668917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03789562T ATE412657T1 (de) | 2002-12-24 | 2003-12-22 | Therapeutische quinazolin-derivate |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20060058325A1 (de) |
| EP (1) | EP1575966B1 (de) |
| JP (1) | JP2006512387A (de) |
| AT (1) | ATE412657T1 (de) |
| AU (1) | AU2003294142A1 (de) |
| DE (1) | DE60324461D1 (de) |
| ES (1) | ES2314271T3 (de) |
| WO (1) | WO2004058782A1 (de) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004058752A1 (en) * | 2002-12-24 | 2004-07-15 | Astrazeneca Ab | Quinazoline compounds |
| RU2005135337A (ru) | 2003-04-16 | 2006-06-10 | Астразенека Аб (Se) | Производные хиназолина для лечения злокачественного новообразования |
| US7572914B2 (en) | 2003-12-19 | 2009-08-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| AU2005231507B2 (en) | 2004-04-08 | 2012-03-01 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
| WO2006023931A2 (en) | 2004-08-18 | 2006-03-02 | Takeda San Diego, Inc. | Kinase inhibitors |
| NZ588896A (en) | 2004-08-25 | 2012-05-25 | Targegen Inc | Heterocyclic compounds and methods of use |
| MX2007004403A (es) | 2004-10-12 | 2007-04-27 | Astrazeneca Ab | Derivados de quinazolina. |
| EP1812439B2 (de) | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Kinaseinhibitoren |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
| WO2007053452A1 (en) | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| WO2007089335A2 (en) | 2005-12-29 | 2007-08-09 | Lexicon Pharmaceutical Inc. | Multicyclic amino acid derivatives and methods of their use |
| ES2433199T3 (es) * | 2006-04-27 | 2013-12-09 | Msd K.K. | Derivados de aminopirimidina que tienen actividad inhibidora selectiva de Aurora-A |
| JP2010505962A (ja) | 2006-10-09 | 2010-02-25 | 武田薬品工業株式会社 | キナーゼ阻害剤 |
| AU2009303602B2 (en) * | 2008-10-14 | 2012-06-14 | Sunshine Lake Pharma Co., Ltd. | Compounds and methods of use |
| AU2010363329A1 (en) | 2010-11-07 | 2013-05-09 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| CN103304489B (zh) * | 2012-03-16 | 2015-03-11 | 中国农业科学院兰州畜牧与兽药研究所 | 嘧啶苯甲酰胺类化合物及其制备和应用 |
| US9353122B2 (en) | 2013-02-15 | 2016-05-31 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| US9353123B2 (en) | 2013-02-20 | 2016-05-31 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| KR20160099084A (ko) | 2013-11-01 | 2016-08-19 | 칼라 파마슈티컬스, 인크. | 치료 화합물의 결정질 형태 및 그의 용도 |
| US10253036B2 (en) | 2016-09-08 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| EP3509421A4 (de) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | Kristalline formen therapeutischer verbindungen und verwendungen davon |
| WO2018048750A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6258820B1 (en) * | 1999-03-19 | 2001-07-10 | Parker Hughes Institute | Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines |
| GB9922171D0 (en) * | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
| HK1046688A1 (zh) * | 1999-09-21 | 2003-01-24 | Astrazeneca Ab | 喹唑啉化合物和含有喹唑啉化合物的藥物組合物 |
| US20030064119A1 (en) * | 2001-06-21 | 2003-04-03 | Emerson Ralph W. | Methods and compositions for applying essential oils and naturally occurring compounds to plants to activate endogenous plant pathogen defense pathways |
-
2003
- 2003-12-22 AT AT03789562T patent/ATE412657T1/de not_active IP Right Cessation
- 2003-12-22 ES ES03789562T patent/ES2314271T3/es not_active Expired - Lifetime
- 2003-12-22 JP JP2004563355A patent/JP2006512387A/ja active Pending
- 2003-12-22 WO PCT/GB2003/005640 patent/WO2004058782A1/en not_active Ceased
- 2003-12-22 DE DE60324461T patent/DE60324461D1/de not_active Expired - Fee Related
- 2003-12-22 EP EP03789562A patent/EP1575966B1/de not_active Expired - Lifetime
- 2003-12-22 AU AU2003294142A patent/AU2003294142A1/en not_active Abandoned
- 2003-12-22 US US10/539,483 patent/US20060058325A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20060058325A1 (en) | 2006-03-16 |
| ES2314271T3 (es) | 2009-03-16 |
| EP1575966A1 (de) | 2005-09-21 |
| JP2006512387A (ja) | 2006-04-13 |
| EP1575966B1 (de) | 2008-10-29 |
| AU2003294142A1 (en) | 2004-07-22 |
| DE60324461D1 (de) | 2008-12-11 |
| WO2004058782A1 (en) | 2004-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60324461D1 (de) | Therapeutische quinazolin-derivate | |
| MY136174A (en) | Phosphonooxy quinazoline derivatives and their pharmaceutical use | |
| MXPA05006920A (es) | Compuestos de quinazolina. | |
| MY141739A (en) | Substituted quinazoline derivatives as inhibitors of aurora kinases | |
| NO20085217L (no) | Effektive pyrimidinderivater i behandlingen av kreft | |
| NO20051695L (no) | Nye spirokondenserte kinazolinoner og deres anvendelse som fosfodiestereaseinbibitorer | |
| SE0101387D0 (sv) | Novel compounds | |
| DE60328010D1 (de) | Heterocyclische verbindungen | |
| SE9904505D0 (sv) | Novel compounds | |
| SE0202463D0 (sv) | Novel compounds | |
| ATE394383T1 (de) | Biphenylkarbonsäureamidderivate als p38 kinase- inhibitoren | |
| ATE302775T1 (de) | Carbolinderivate | |
| DE60206911D1 (de) | Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren | |
| HUP0400246A2 (hu) | 1,2,4-Trioxolánt tartalmazó maláriaellenes gyógyszerkészítmények és eljárás az előállításukra és az alkalmazásukra | |
| DE60121461D1 (de) | Kondensierte pyridoindolderivate | |
| ATE346067T1 (de) | Carbolinderivate | |
| GB0308201D0 (en) | Novel compounds | |
| SE0301699D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| ATE333457T1 (de) | Zyklische gmp-spezifische phosphodiesteraseinhibitoren | |
| DE60013486D1 (de) | Verbindungen | |
| DE60305053D1 (de) | Pyrimidinderivate als selektive cox-2-inhibitoren | |
| AU2001296699A1 (en) | Condensed pyrazindione derivatives as pde inhibitors | |
| UA86470C2 (ru) | Производные фосфонооксихиназолина и их фармацевтическое применение | |
| DK1789044T3 (da) | Phenylaminopyridiner og phenylaminopyraziner | |
| ATE343576T1 (de) | 7-azaindolderivate als cox2-inhibitoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |